Target intelligence / Profile preview

Pyrimidine synthesis pathway

Molecular classification
Other (Metabolic pathway)
01

Overview

The **pyrimidine synthesis pathway** is a fundamental metabolic process responsible for generating pyrimidine nucleotides—essential building blocks for DNA and RNA. This process occurs via two main routes: 1. **De novo synthesis**, which constructs pyrimidines from simple precursors like glutamine, bicarbonate, aspartate, and ATP through a series of enzymatic steps. 2. **Salvage pathways**, which recycle preformed bases from degraded nucleic acids[1][3][5]. Key enzymes involved include carbamoyl phosphate synthetase II (CPS II), aspartate transcarbamoylase (ATCase), dihydroorotase (DHOase), dihydroorotate dehydrogenase (DHODH), orotate phosphoribosyltransferase (OPRT), and OMP decarboxylase[7]. The end products are uridine monophosphate (UMP) and cytidine triphosphate (CTP), vital for nucleic acid biosynthesis. This metabolic network is tightly regulated by feedback inhibition mechanisms; for example, UTP inhibits CPS II activity to prevent overproduction[5][7]. Dysregulation or genetic defects in this pathway can lead to diseases such as cancer or hereditary orotic aciduria. While individual enzymes within the pyrimidine synthesis pathway—such as DHODH—are considered therapeutic targets with drugs like leflunomide acting upon them[4], the entire "pyrimidine synthesis pathway" itself is not a single molecular target but rather a collection of enzymatic activities forming a biochemical route. **Note:** The entry "Pyrimidine synthesis pathway" refers to an entire metabolic process rather than an individual molecule/receptor/target. For structured drug discovery purposes, it is more appropriate to specify one of its constituent enzymes such as "Dihydroorotate dehydrogenase" when referring to actionable therapeutic targets[4].

Other names
De novo pyrimidine synthesis pathwayPyrimidine biosynthesisPyrimidine nucleotide metabolismPyrimidine salvage pathway
02

Mechanism of action

Inhibition of key enzymes in the pyrimidine synthesis pathway (e.g., DHODH inhibition blocks de novo pyrimidine production and impairs rapidly dividing cells)

03

Biological functions

DNA synthesisRNA synthesisNucleotide metabolismCell proliferation
04

Disease associations

CancerImmunodeficiency disorders (e.g., orotic aciduria)
05

Safety considerations

Inhibition can cause cytopenias, immunosuppressiongastrointestinal toxicity due to effects on rapidly dividing cells
06

Interacting drugs

Leflunomide (inhibits DHODH)
07

Biomarkers

Orotic acid levels (for defects in the pathway such as orotic aciduria)

Beyond the preview

Go deeper on Pyrimidine synthesis pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyrimidine synthesis pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call